dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 4, 2026

JPMorgan Lowers its Price Target on McCormick & Company. (MKC) to $64

View original at finance.yahoo.com
JPMorgan Lowers its Price Target on McCormick & Company. (MKC) to $64 McCormick & Company, Incorporated (NYSE:MKC) is one of the 10 Best Stocks That Beat Earnings Estimates…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • McCormick price target lowered to $64 from $67 with Overweight rating maintained

    60% confidence

  • McCormick is not receiving the 'benefit of the doubt' from investors regarding its food deal

    60% confidence

  • Volumes were in line with expectations and anticipates sequential improvement through the year, supported by brand investments, innovation, and distribution gains

    60% confidence

  • FY26 adjusted EPS guidance of $3.05-$3.13 versus $3.09 consensus

    60% confidence

  • The company delivered growth in sales, operating income, and earnings per share, supported by the McCormick de Mexico acquisition and organic growth across both segments, alongside cost discipline that drove margin expansion

    60% confidence

  • Expected revenue growth of 13%-17% for FY26

    60% confidence

  • Certain AI stocks offer greater upside potential and carry less downside risk than MKC

    60% confidence

  • Projected tax rate of 24% for FY26

    60% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
JPMorgan Lowers its Price Target on McCormick & Company. (MKC) to $64: Source | Via News | fr.via.news